Saturday 17 October 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.
14.07
0.34
−2.36%
Follow NVCR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.25 | 2.20 | 1.84 | 2.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
70.28 | (80.06) | (92.05) | 216.13 | |
P/B ratio |
4.24 | 4.23 | 3.76 | 5.20 | |
Price to Tangible BV |
4.24 | 4.23 | 3.76 | 5.20 | |
EV/Sales |
0.94 | 1.80 | 1.54 | 2.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(17.53) | (24.04) | (38.59) | (533.92) | |
EV/FCF |
(9.27) | (15.58) | (21.58) | (59.09) | |
Quick Ratio |
1.50 | 2.71 | 2.70 | 2.70 | |
Current Ratio |
1.55 | 2.90 | 2.90 | 2.89 | |
Net Debt/EBITDA |
21.71 | 6.57 | 3.14 | 28.77 | |
Debt/Assets |
14.30% | 24.25% | 29.82% | 24.63% | |
Debt/Equity |
0.57 | 0.57 | 0.71 | 0.58 | |
Asset Turnover |
0.50 | 0.64 | 0.66 | 0.69 | |
Operating CF/Net income |
(0.55) | 0.73 | 0.19 | (0.52) | |
Capex/Depreciation |
2.06 | (10.37) | (3.42) | (4.03) | |
Interest Coverage |
6.00 | (72.00) | (36.68) | (5.59) | |
Research and Development Expense of Revenue |
32.31% | 34.93% | 33.52% | 28.02% | |
Selling, General and Administrative Expense of Revenue |
62.48% | 64.06% | 82.85% | 55.34% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.54% | 11.37% | 36.20% | 9.27% | |
Graham Net Nets |
0.12 | 0.13 | 0.14 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.46%) | (9.44%) | (14.04%) | (8.58%) | |
Free Cash Flow Yield |
(4.51%) | (5.25%) | (3.86%) | (1.45%) | |
Revenue per Share |
1.49 | 1.56 | 1.52 | 1.58 | |
Operating CF per Share |
0.18 | (0.16) | (0.12) | 0.07 | |
Capex per Share |
(0.05) | (0.04) | (0.05) | (0.06) | |
Free Cash Flow per Share |
0.13 | (0.21) | (0.16) | 0.01 | |
Cash per Share |
9.26 | 4.10 | 3.87 | 3.88 | |
Shareholders Equity per Share |
3.05 | 3.05 | 2.90 | 2.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.05 | 3.05 | 2.90 | 2.91 | |
Free Cash Flow |
14.92 | (22.90) | (18.67) | 1.22 | |
Working Capital |
423.85 | 423.50 | 414.09 | 417.81 | |
Capital Expenditures |
(5.65) | (4.90) | (5.15) | (6.92) | |
Net Current Asset Value |
179.99 | 182.87 | 174.45 | 181.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
108.61 | 128.70 | 132.48 | 137.44 | |
Average Payables |
105.12 | 113.66 | 111.16 | 117.20 | |
Average Inventory |
39.10 | 38.10 | 41.46 | 41.22 | |
Average Assets |
1,291.59 | 1,022.56 | 1,018.37 | 1,020.53 | |
Average Common Equity |
351.06 | 350.32 | 346.34 | 343.77 |
Columns are period end dates